<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01088919</url>
  </required_header>
  <id_info>
    <org_study_id>1941-CL-0060</org_study_id>
    <nct_id>NCT01088919</nct_id>
  </id_info>
  <brief_title>A Study to Characterize the Effect on the Pharmacokinetics of ASP1941 and Pioglitazone Hydrochloride When Given Together to Healthy Subjects</brief_title>
  <official_title>A Phase 1, Open Label, Randomized, Crossover, Drug Interaction Study of the Pharmacokinetics of ASP1941 and Pioglitazone Hydrochloride After Separate and Concomitant Administration to Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate pharmacokinetics, pharmacodynamics and safety
      following the administration of ASP1941 and pioglitazone hydrochloride in multiple and single
      doses.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All subjects will be enrolled at one center and confined to the unit for up to 23 days.
      Subjects will be dosed in the fasting state in one of the four groups.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic variables assessment through analysis of blood samples</measure>
    <time_frame>Day 1 and up to Day 21</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic variables assessment through analysis of blood and urine samples</measure>
    <time_frame>Day -1 and up to Day 17</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by recording of adverse events, laboratory assessments, electrocardiograms (ECGs), vital signs and physical examinations</measure>
    <time_frame>Day 1 through scheduled group check out (Day 13 and up to Day 21) or early termination</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Healthy</condition>
  <condition>Pharmacokinetics of ASP1941</condition>
  <arm_group>
    <arm_group_label>Dosing Regimen 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dosing Regimen 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dosing Regimen 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dosing Regimen 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASP1941</intervention_name>
    <description>oral tablet</description>
    <arm_group_label>Dosing Regimen 1</arm_group_label>
    <arm_group_label>Dosing Regimen 2</arm_group_label>
    <arm_group_label>Dosing Regimen 3</arm_group_label>
    <arm_group_label>Dosing Regimen 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pioglitazone hydrochloride</intervention_name>
    <description>oral tablet</description>
    <arm_group_label>Dosing Regimen 1</arm_group_label>
    <arm_group_label>Dosing Regimen 2</arm_group_label>
    <arm_group_label>Dosing Regimen 3</arm_group_label>
    <arm_group_label>Dosing Regimen 4</arm_group_label>
    <other_name>Actos</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The subject weighs at least 50 kg, and has a body mass index (BMI) of 18 to 32 kg/m2
             inclusive

          -  The subject's 12-lead electrocardiogram (ECG) results are normal

          -  The female subject must be at least two years postmenopausal, surgically sterile or
             practicing effective birth control and not pregnant or lactating

          -  The male or female subject agrees to practice highly effective birth control from
             Screening until 7 days post last dose

        Exclusion Criteria:

          -  The subject has a history or evidence of any clinically significant (as determined by
             the investigator) cardiovascular, endocrinologic, hematologic, hepatic, immunologic,
             metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, and/or
             other major disease or malignancy (excluding non-melanoma skin cancer)

          -  The subject has any condition possibly affecting drug absorption (e.g., gastrectomy)

          -  The subject has history of consuming more than 14 units of alcoholic beverages per
             week within 6 months prior to screening or has a history of alcoholism or
             drug/chemical/substance abuse within past 2 years prior to screening or the subject
             tests positive for alcohol or drugs of abuse

          -  The subject has/had febrile illness or symptomatic, viral, bacterial (including upper
             respiratory infection), or fungal (non-cutaneous) infection within 1 week prior to
             clinic check in

          -  The subject has a supine mean systolic blood pressure &lt; 90 or &gt; 160 mmHg and a mean
             diastolic blood pressure &lt; 50 or &gt; 90 mmHg, or pulse rate higher than 100 beats per
             min (bpm)

          -  The subject has a 12-lead ECG demonstrating QTc &gt;470 msec (female) or &gt;450 msec (male)

          -  The subject is known positive for human immunodeficiency virus (HIV) antibody

          -  The subject has a positive test for tuberculosis (TB), hepatitis C antibody, or
             positive for hepatitis B antigen (HBsAg)

          -  The subject has used prescription or non-prescription drugs within 2 weeks or 5
             half-lives (whichever is longer) or complementary and alternative medicines (CAM)
             within 14 days prior to study drug administration (excluding oral contraceptives,
             hormone replacement therapy [HRT], and acetaminophen)

          -  The subject has had any significant blood loss, donated one unit (450 mL) of blood or
             more, or received a transfusion of any blood or blood products within 60 days or
             donated plasma within 7 days prior to clinic admission
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Use Central Contact</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Global Development</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 4, 2010</study_first_submitted>
  <study_first_submitted_qc>March 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2010</study_first_posted>
  <last_update_submitted>April 15, 2010</last_update_submitted>
  <last_update_submitted_qc>April 15, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 16, 2010</last_update_posted>
  <responsible_party>
    <name_title>Sr Manager Clinical Trials Registry</name_title>
    <organization>Astellas Pharma Global Development</organization>
  </responsible_party>
  <keyword>ASP1941</keyword>
  <keyword>Actos</keyword>
  <keyword>pioglitazone hydrochloride</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

